Lilly: Lung Cancer Drug Meets Phase III Endpoint

barbara.lempert

Announces III Necitumumab Study Primary of Overall Survival
Study found improved overall survival in patients with stage IV squamous NSCLC

INDIANAPOLIS, Aug. 13, 2013 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced that SQUIRE, a recently completed Phase III study, met its primary endpoint, finding that patients with stage IV metastatic squamous non-small cell (NSCLC) experienced increased overall survival (OS) when administered necitumumab (IMC-11F8) in combination with gemcitabine and cisplatin as a first-line treatment, as compared to chemotherapy alone.

The most common adverse events occurring more frequently in patients on the necitumumab arm were rash and hypomagnesemia. Serious, but less frequent, adverse events occurring more often on the necitumumab arm included thromboembolism.

“We are pleased with these data which represent a potential advance in treatment for patients with squamous non-small cell lung cancer, which is a difficult cancer to treat,” said Richard Gaynor, M.D., vice president, product development and medical affairs for Lilly Oncology. “If approved, necitumumab could be the first biologic therapy indicated to treat patients with squamous lung cancer.”

Lung cancer is the leading cause of cancer death in the US and most other countries. [1] Non-small cell lung cancer (NSCLC) is much more common than other types of lung cancer, and accounts for 85 percent of all lung cancer cases. [2] Patients with squamous cell carcinoma represent about 30% of all patients affected by NSCLC.1

Lilly plans to present results from this study at a scientific meeting in 2014, and currently anticipates submitting to regulatory authorities before the end of 2014.

About the Study

SQUIRE enrolled 1093 patients (age greater than or equal to 18 years, ECOG PS 0-2) with histologically- or cytologically-confirmed, stage IV squamous NSCLC, who had received…Read more

Pharmalive – The Pulse of the Pharmaceutical Industry

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS